Hospital
Johnson Regional Medical Center
Johnson Regional Medical Center was paid $4.51M by Medicaid between Jan 2018 and Dec 2024, across 136 billing codes. Its largest line is 87502, Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets — 12% of everything it billed.
33Billing provider infoJOHNSON REGIONAL MEDICAL CENTER
CLARKSVILLE, AR 72830
CLARKSVILLE, AR 72830
33aNPI1134116049assigned 10/05/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.51M
24GClaims201,666
24DCodes billed136
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arkansas
Rank by total paid#17 of 49
Median peer was paid$2.62M
This provider vs. median1.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 27,700 | $418K | |
| 2019 | 32,390 | $692K | |
| 2020 | 28,819 | $539K | |
| 2021 | 29,890 | $628K | |
| 2022 | 28,665 | $756K | |
| 2023 | 28,994 | $777K | |
| 2024incomplete | 25,208 | $703K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 12% | 5,155 | 4,722 | $542K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 7.8% | 11,381 | 2,587 | $351K |
| 80053 | Comprehensive metabolic panel | 6.2% | 15,317 | 11,960 | $280K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.8% | 1,937 | 1,715 | $263K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 5.3% | 3,327 | 2,381 | $239K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.0% | 2,159 | 1,912 | $226K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 4.6% | 4,467 | 4,121 | $207K |
| 87634 | 3.6% | 2,028 | 1,923 | $164K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.2% | 19,929 | 15,374 | $146K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.4% | 1,436 | 1,195 | $110K |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 2.4% | 2,202 | 1,586 | $110K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.4% | 2,005 | 1,622 | $108K |
124 more codes
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | 2.1% | 3,310 | $94K |
| 99284 | Emergency room visit (serious) | 1.9% | 2,922 | $86K |
| 99285 | Emergency room visit (most serious) | 1.9% | 3,096 | $86K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.6% | 567 | $74K |
| A0425 | Ground mileage, per statute mile | 1.6% | 2,940 | $71K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.5% | 961 | $66K |
| 81001 | 1.4% | 10,943 | $62K | |
| 97161 | 1.3% | 1,176 | $61K | |
| 59025 | Fetal non-stress test | 1.3% | 644 | $59K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 5,662 | $58K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.2% | 6,107 | $54K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 5,999 | $48K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 1.0% | 194 | $47K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,502 | $39K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 1,246 | $35K |
| 84484 | <1% | 4,216 | $32K | |
| 81025 | <1% | 3,793 | $31K | |
| 87077 | <1% | 3,320 | $31K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,568 | $31K |
| 86901 | <1% | 1,153 | $30K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 861 | $30K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 115 | $27K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,462 | $27K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,325 | $26K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,224 | $25K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 110 | $24K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,055 | $23K |
| 87040 | <1% | 1,939 | $22K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 67 | $22K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,870 | $21K |
| 82553 | <1% | 2,372 | $20K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,375 | $18K |
| 83880 | <1% | 752 | $18K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 424 | $18K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 409 | $17K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,846 | $16K |
| 83690 | <1% | 2,274 | $15K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,941 | $15K |
| 87186 | <1% | 2,394 | $15K | |
| 82550 | <1% | 2,707 | $14K | |
| 87070 | <1% | 1,308 | $13K | |
| 82803 | <1% | 393 | $13K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,056 | $12K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 628 | $11K |
| 74018 | <1% | 522 | $10K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 894 | $9K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 308 | $9K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 51 | $9K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,716 | $9K |
| 85027 | <1% | 1,307 | $8K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 30 | $7K |
| 74022 | <1% | 318 | $7K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 145 | $7K |
| 85730 | <1% | 1,421 | $6K | |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | <1% | 171 | $6K |
| 85378 | <1% | 836 | $6K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 123 | $5K |
| 86885 | <1% | 768 | $5K | |
| 85610 | <1% | 1,853 | $5K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 47 | $5K |
| 82150 | <1% | 790 | $5K | |
| 82951 | <1% | 292 | $5K | |
| 73610 | <1% | 296 | $5K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 96 | $4K |
| 85007 | <1% | 1,302 | $4K | |
| 87807 | <1% | 333 | $4K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 25 | $4K |
| 73630 | <1% | 179 | $4K | |
| 80061 | Lipid panel | <1% | 237 | $4K |
| 71020 | <1% | 249 | $3K | |
| 86592 | <1% | 727 | $3K | |
| 86762 | <1% | 184 | $3K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 15 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 266 | $3K |
| 83605 | <1% | 288 | $3K | |
| 86803 | <1% | 160 | $3K | |
| 86900 | <1% | 791 | $3K | |
| 84439 | <1% | 283 | $2K | |
| 87340 | <1% | 174 | $2K | |
| 97001 | <1% | 60 | $2K | |
| 81002 | <1% | 761 | $2K | |
| 73110 | <1% | 89 | $2K | |
| 95811 | <1% | 13 | $2K | |
| 84702 | <1% | 180 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,106 | $2K |
| 71010 | <1% | 220 | $2K | |
| 73130 | <1% | 76 | $2K | |
| 73030 | <1% | 82 | $2K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 74 | $1K |
| 96376 | <1% | 316 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 520 | $1K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 183 | $974.29 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,070 | $959.84 |
| 83735 | <1% | 161 | $839.57 | |
| 73560 | <1% | 40 | $821.95 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 562 | $636.21 |
| 80050 | General health panel | <1% | 13 | $632.71 |
| 82670 | <1% | 17 | $558.74 | |
| 84703 | <1% | 51 | $471.13 | |
| 73502 | <1% | 14 | $446.89 | |
| 84403 | <1% | 18 | $442.44 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,633 | $439.23 |
| 84402 | <1% | 18 | $399.96 | |
| 72100 | <1% | 12 | $357.89 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 563 | $324.13 |
| 83001 | <1% | 17 | $294.85 | |
| 74000 | <1% | 14 | $260.00 | |
| 90714 | <1% | 26 | $214.73 | |
| 84450 | <1% | 34 | $177.12 | |
| 82962 | <1% | 52 | $157.98 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 30 | $148.97 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 158 | $106.81 |
| 83540 | <1% | 22 | $92.50 | |
| 82947 | <1% | 14 | $81.81 | |
| 82565 | <1% | 17 | $80.41 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 155 | $79.10 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 53 | $51.90 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 817 | $46.80 |
| 85014 | <1% | 15 | $33.80 | |
| 85018 | <1% | 15 | $33.80 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 303 | $27.34 |
| 36600 | <1% | 243 | $9.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 22 | $2.07 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 41 | $0.11 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMORSE, ROBERT (ADMINISTRATOR)
| Provider | Location | Paid |
|---|---|---|
| Johnson Regional Medical Center | Clarksville, AR | $702K |
| Johnson Regional Medical Center | Clarksville, AR | $89K |
| Johnson Regional Medical Center | Clarksville, AR | $3K |
| Johnson Regional Medical Center | Clarksville, AR | $9.70 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.